LivaNova PLC (NASDAQ:LIVN) Stock Holdings Lowered by State of Michigan Retirement System

State of Michigan Retirement System trimmed its holdings in shares of LivaNova PLC (NASDAQ:LIVN) by 1.5% in the second quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 13,011 shares of the company’s stock after selling 200 shares during the period. State of Michigan Retirement System’s holdings in LivaNova were worth $713,000 as of its most recent SEC filing.

Several other hedge funds have also recently added to or reduced their stakes in LIVN. BNP Paribas Financial Markets boosted its stake in shares of LivaNova by 98.3% during the 4th quarter. BNP Paribas Financial Markets now owns 22,338 shares of the company’s stock worth $1,156,000 after acquiring an additional 11,075 shares in the last quarter. Dimensional Fund Advisors LP raised its holdings in LivaNova by 6.3% during the 4th quarter. Dimensional Fund Advisors LP now owns 1,241,985 shares of the company’s stock worth $64,262,000 after buying an additional 74,067 shares during the period. Principal Financial Group Inc. lifted its stake in LivaNova by 2.4% during the fourth quarter. Principal Financial Group Inc. now owns 225,385 shares of the company’s stock valued at $11,661,000 after buying an additional 5,329 shares in the last quarter. Vanguard Personalized Indexing Management LLC boosted its holdings in shares of LivaNova by 34.6% in the fourth quarter. Vanguard Personalized Indexing Management LLC now owns 5,521 shares of the company’s stock worth $286,000 after buying an additional 1,418 shares during the period. Finally, Panagora Asset Management Inc. increased its position in shares of LivaNova by 183.7% in the fourth quarter. Panagora Asset Management Inc. now owns 157,899 shares of the company’s stock worth $8,170,000 after acquiring an additional 102,235 shares in the last quarter. Institutional investors and hedge funds own 97.64% of the company’s stock.

LivaNova Trading Up 0.3 %

NASDAQ LIVN opened at $50.39 on Friday. The company has a market capitalization of $2.73 billion, a PE ratio of -83.98 and a beta of 0.99. LivaNova PLC has a 1-year low of $42.75 and a 1-year high of $64.47. The company has a current ratio of 3.45, a quick ratio of 2.71 and a debt-to-equity ratio of 0.49. The firm’s fifty day simple moving average is $50.02 and its 200-day simple moving average is $53.84.

Insiders Place Their Bets

In other news, Director Daniel Jeffrey Moore sold 56,623 shares of LivaNova stock in a transaction dated Monday, June 3rd. The stock was sold at an average price of $60.11, for a total transaction of $3,403,608.53. Following the completion of the sale, the director now directly owns 27,534 shares in the company, valued at approximately $1,655,068.74. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Insiders own 0.27% of the company’s stock.

Analyst Ratings Changes

Several equities research analysts recently commented on LIVN shares. Robert W. Baird restated a “neutral” rating and issued a $55.00 price target on shares of LivaNova in a research report on Wednesday. Stifel Nicolaus increased their target price on LivaNova from $70.00 to $72.00 and gave the company a “buy” rating in a report on Thursday, July 25th. Finally, Needham & Company LLC upped their price target on LivaNova from $72.00 to $75.00 and gave the company a “buy” rating in a research report on Wednesday, July 31st. Three investment analysts have rated the stock with a hold rating and four have given a buy rating to the company. According to MarketBeat, LivaNova presently has an average rating of “Moderate Buy” and a consensus price target of $65.83.

About LivaNova

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.